

Vice President at Pennsylvania State University, will provide a classified briefing on semiconductor manufacturing. Next, DSB Members will deliberate and vote on the DSB Task Force to Advise Implementation and Prioritization of National Security Innovation Activities executive summary; the DSB Task Force on Digital Engineering Capability to Automate Testing and Evaluation report/executive summary; and the DSB 2024 Summer Study on Climate Change and Global Security report/executive summary. Following break, Dr. William LaPlante, Under Secretary for Acquisition and Sustainment (A&S), will provide a classified briefing on his views of current A&S strategy, challenges, and priorities. Finally, DSB members will have a classified plenary discussion regarding briefer remarks and ongoing studies. The meeting will adjourn at 3:30 p.m.

**Meeting Accessibility:** In accordance with 5 U.S.C. 1009(d) and 41 CFR 102–3.155, the DoD has determined that the DSB meeting will be closed to the public. Specifically, the USD(R&E), in consultation with the DoD Office of the General Counsel, has determined in writing that the meeting will be closed to the public because it will consider matters covered by 5 U.S.C. 552b(c)(1). The determination is based on the consideration that it is expected that discussions throughout will involve classified matters of national security concern. Such classified material is so intertwined with the unclassified material that it cannot reasonably be segregated into separate discussions without defeating the effectiveness and meaning of the overall meetings. To permit the meeting to be open to the public would preclude discussion of such matters and would greatly diminish the ultimate utility of the DSB's findings and recommendations to the Secretary of Defense and to the USD(R&E).

**Written Statements:** In accordance with 5 U.S.C. 1009(a)(3) and 41 CFR 102–3.105(j) and 102–3.140, interested persons may submit a written statement for consideration by the DSB at any time regarding its mission or in response to the stated agenda of a planned meeting. Individuals submitting a written statement must submit their statement to the DSB DFO at the email address provided in the **FOR FURTHER INFORMATION CONTACT** section at any point; however, if a written statement is not received at least three calendar days prior to the meeting, which is the subject of this notice, then it may not be provided to or considered by the DSB until a later date.

Dated: April 23, 2024.

**Aaron T. Siegel,**

*Alternate OSD Federal Register Liaison Officer, Department of Defense.*

[FR Doc. 2024–09088 Filed 4–26–24; 8:45 am]

**BILLING CODE 6001–FR–P**

## DEPARTMENT OF DEFENSE

### Office of the Secretary

#### Uniform Formulary Beneficiary Advisory Panel; Notice of Federal Advisory Committee Meeting

**AGENCY:** Under Secretary of Defense for Personnel and Readiness (USD(P&R)), Department of Defense (DoD).

**ACTION:** Notice of Federal advisory committee meeting.

**SUMMARY:** The DoD is publishing this notice to announce that the following Federal Advisory Committee meeting of the Uniform Formulary Beneficiary Advisory Panel (UFBAP) will take place.

**DATES:** Open to the public Wednesday, June 26, 2024, from 10:00 a.m. to 1:00 p.m. Eastern Standard Time.

**ADDRESSES:** The meeting will be held telephonically or via conference call. The phone number for the remote access on June 26, 2024, is: CONUS: 1–888–831–4306; OCONUS: 1–210–234–8694; PARTICIPANT CODE: 9136304.

These numbers and the dial-in instructions will also be posted on the UFBAP website at: <https://www.health.mil/Military-Health-Topics/Access-Cost-Quality-and-Safety/Pharmacy-Operations/BAP>.

**FOR FURTHER INFORMATION CONTACT:** Designated Federal Official (DFO) Captain Tiffany F. Cline, USN, 703–681–2890 (voice), [dha.ncr.j-6.mbx.baprequests@health.mil](mailto:dha.ncr.j-6.mbx.baprequests@health.mil) (email). Mailing address is 7700 Arlington Boulevard, Suite 5101, Falls Church, VA 22042–5101. Website: <https://www.health.mil/Military-Health-Topics/Access-Cost-Quality-and-Safety/Pharmacy-Operations/BAP>. The most up-to-date changes to the meeting agenda can be found on the website.

**SUPPLEMENTARY INFORMATION:** This meeting is being held under the provisions of chapter 10 of title 5, United States Code (U.S.C.) (commonly known as “the Federal Advisory Committee Act” or “FACA”), 5 U.S.C. 552b (commonly known as the “Government in the Sunshine Act”), and 41 CFR 102–3.140 and 102–3.150.

**Purpose of the Meeting:** The UFBAP will review and comment on recommendations made by the Pharmacy and Therapeutics Committee

to the Director, Defense Health Agency regarding the Uniform Formulary.

#### Agenda:

1. 10:00 a.m.–10:10 a.m. Sign in for UFBAP members
2. 10:10 a.m.–10:40 a.m. Welcome and Opening Remarks
  - a. Welcome, Opening Remarks, and Introduction of UFBAP Members by CAPT Tiffany F. Cline, DFO, UFBAP
  - b. Public Written Comments by CAPT Tiffany F. Cline, DFO, UFBAP
  - c. Opening Remarks by Dr. Pamela Schweitzer, UFBAP Chair
  - d. Introductory Remarks by Dr. Edward Vonberg, Chief, Formulary Management Branch
3. 10:40 a.m.–11:45 a.m. Scheduled Therapeutic Class Reviews
4. 11:45 a.m.–12:30 p.m. Newly Approved Drugs Review
5. 12:30 p.m.–12:45 p.m. Pertinent Utilization Management Issues
6. 12:45 p.m.–1:00 p.m. Closing remarks
  - a. Closing Remarks by UFBAP Co-Chair
  - b. Closing Remarks by DFO, UFBAP

**Meeting Accessibility:** Pursuant to 5 U.S.C. 1009(a)(1) and 41 CFR 102–3.165, and subject to the availability of phone lines, this meeting is open to the public. Telephone lines are limited and available to the first 220 people dialing in. There will be 220 lines total: 200 domestic and 20 international, including leader lines.

**Written Statements:** Pursuant to 41 CFR 102–3.105(j) and 102–3.140(c), and 5 U.S.C. 1009(a)(3), interested persons or organizations may submit written statements to the UFBAP about its mission and/or the agenda to be addressed in this public meeting. Written statements should be submitted to the UFBAP's DFO. The DFO's contact information can be found in the **FOR FURTHER INFORMATION CONTACT** section of this notice. Written comments or statements must be received by the UFBAP's DFO at least five (5) calendar days prior to the meeting so they may be made available to the UFBAP for its consideration prior to the meeting. Written comments received are releasable to the public. The DFO will review all submitted written statements and provide copies to UFBAP.

Dated: April 23, 2024.

**Aaron T. Siegel,**

*Alternate OSD Federal Register Liaison Officer, Department of Defense.*

[FR Doc. 2024–09080 Filed 4–26–24; 8:45 am]

**BILLING CODE 6001–FR–P**